Project Grant R21CA318035
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded $410,545 to The Research Foundation For The State University of New York under the Cancer Treatment Research program (CFDA 93.395) for a Project Grant effective May 1, 2026 through April 30, 2028. The award supports research assessing the role of efflux transport mechanisms, pharmacokinetics, and systems pharmacology in monomethyl auristatin E (MMAE)-induced neurotoxicity associated with antibody-drug conjugate (ADC)...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Sloan-Kettering Institute for Cancer Research a $731,503 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) effective June 1, 2026 through May 31, 2031. This grant funds a randomized controlled trial (RCT) evaluating Brief Behavioral Activation (BBA) as a telehealth-delivered intervention for treating depression in older adult cancer survivors (OACS) aged 65 and older. The research addresses a...
- Federal Grant Award Summary The National Cancer Institute (NCI), under the Cancer Cause and Prevention Research program (CFDA 93.393), awarded the University of Alabama a Project Grant of $2,524,071 on September 23, 2025, for research investigating the neurocomputational mechanisms underlying self-regulation and reinforcement learning in smoking cessation decisions. The four-year project, with completion scheduled for August 31, 2029, will employ computational model-based multimodal neuroimaging...
- Federal Project Grant Award Summary New York University received a $427,085 Project Grant from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) awarded on August 7, 2025, with completion targeted for July 31, 2027. The grant funds research investigating the relationship between social determinants of health (SDOH)—including food insecurity, dietary quality, and neighborhood-level socioeconomic factors—and cancer-related fatigue (CRF) in...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Sloan-Kettering Institute for Cancer Research a $745,458 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) for the period July 1, 2026 through June 30, 2031. The award funds development and implementation of the PERSON Intervention, an innovative digital health solution designed to facilitate person-centered communication between oncology patients and clinicians. The intervention...
- Federal Project Grant Award Summary New York University received a $442,750 Project Grant award from the National Cancer Institute under the Cancer Cause and Prevention Research program (CFDA 93.393), with performance extending from September 23, 2025 through August 31, 2027. This research initiative delivers a systematic, theory-driven analysis of implementation strategies for cervical cancer control policies in African low- and middle-income countries (LMICs). The project employs a rigorous...
- Federal Project Grant Award Summary New York University School of Medicine received a $310,185 Project Grant from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393), effective July 1, 2026 through June 30, 2029. This R34 planning grant supports the development and feasibility testing of a mobile application designed to deliver the Financial Freedom from Cigarettes (FIERCE) intervention—an evidence-based program that integrates financial...
- Federal Grant Award Summary The University of Virginia received a $415,257 Project Grant from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393), effective July 1, 2026 through June 30, 2028. The grant funds development of a comprehensive intervention to address financial toxicity (FT)—a multidimensional construct encompassing material burden, psychosocial distress, and coping behaviors driven by financial strain—among cancer survivors and...
- Federal Grant Award Summary The National Cancer Institute awarded a $164,484 Project Grant to The University of Kentucky Research Foundation on August 11, 2025, under the Cancer Cause and Prevention Research program (CFDA 93.393). This award supports a research initiative focused on developing and evaluating health communications targeting adults who smoke nondaily (ASN)—a population representing approximately one-third of current adult cigarette smokers in the United States yet demonstrating...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc., a Project Grant of $734,942 under the Cancer Cause and Prevention Research program (CFDA 93.393) effective August 1, 2025, through July 31, 2030. This project addresses cardiovascular disease (CVD) risk in breast cancer survivors by generating novel DNA methylation biomarker data from the Pathways Study, a prospective cohort of 4,504 women diagnosed with...
The National Cancer Institute (NCI) awarded The Research Foundation for the State University of New York a $467,581 Project Grant (CFDA 93.393: Cancer Cause and Prevention Research) effective July 1, 2026, through June 30, 2028, to conduct research on the mechanisms of substance use behaviors among young adult cancer survivors. The research employs a mixed-methods ecological momentary assessment approach to identify socioecological drivers of substance use—including motives, distress, late effects, and social factors—in young adult cancer survivors during early survivorship. This investigation addresses a critical evidence gap, as young adult cancer survivors (ages 18–39) report significantly elevated rates of tobacco, alcohol, cannabis, and illicit drug use compared to non-cancer peers and are four times more likely to develop long-term opioid use, yet no evidence-based substance use interventions tailored to this population currently exist. The research deliverables include an in-depth characterization of substance use mechanisms through an exploratory sequential mixed-methods design, informed by active engagement with young adult cancer survivors and healthcare providers as research partners throughout all phases of the investigation. By identifying the underlying mechanisms driving substance use in this vulnerable population, the project will generate foundational evidence necessary for developing targeted behavioral interventions to mitigate harms including increased cancer recurrence risk, overdose, psychosocial impairment, and exacerbation of late effects such as pain. The work aligns with the National Institutes of Health Stage Model for behavioral intervention development and incorporates patient-centered research principles.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $467.6k | 7/1/26 |